oxybutynin has been researched along with Hypercalcemia in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Hypercalcemia: Abnormally high level of calcium in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 5.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 1.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kusamori, K | 1 |
| Katsumi, H | 1 |
| Abe, M | 1 |
| Ueda, A | 1 |
| Sakai, R | 1 |
| Hayashi, R | 1 |
| Hirai, Y | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Sakane, T | 1 |
| Yamamoto, A | 1 |
1 other study available for oxybutynin and Hypercalcemia
| Article | Year |
|---|---|
Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Butylated Hydroxytoluene; Calcium; Female; G | 2010 |